Detailed Narrative
Strong Q3 FY25 Performance and Geographic Growth
Cipla delivered its highest-ever quarterly revenue of ₹7,073 crores, marking an 8% year-on-year growth. This was supported by robust performance across key geographies, with the One India business growing 10% YoY, One Africa achieving 9% YoY growth in USD terms (21% in ZAR terms for South Africa), and EMEU recording a strong 20% YoY growth in USD terms. The company's chronic mix in Branded Prescriptions improved to 61.5% as per IQVIA MAT December '24, and it added five brands with revenue over ₹100 crores, bringing the total to 26.
Record Profitability and Margin Expansion
The quarter saw an all-time high EBITDA margin of 28%, an increase of 184 basis points YoY and 138 basis points QoQ. Gross margin also improved to 68%, 166 basis points above the previous year, primarily due to overall mix change. Profit after tax stood at ₹1,571 crores, representing 22% of sales. However, management clarified that this 28% EBITDA margin is not sustainable for future quarters, attributing it to seasonal respiratory uptick and specific mix effects.
US Market Dynamics and Product Pipeline
North America delivered a quarterly revenue rate of $226 million, with Albuterol market share reaching 21%. Key US product launches, Advair and Abraxane, are now slated for H2 FY26, with Advair from the US facility and Abraxane from the Goa facility post-approval. The delays are primarily due to regulatory clearance and manufacturing ramp-up. The company also has a pipeline of two to three respiratory assets expected in 18-24 months and other peptide assets, aiming for a significant ramp-up in its US respiratory portfolio.
Regulatory Updates and Quality Initiatives
Cipla's Goa facility received a VAI Classification from the US FDA, a positive development. However, the Virgonagar and Medispray facilities were inspected, receiving eight and one 483 observations, respectively, with official classifications pending. Management emphasized its ongoing efforts to strengthen quality systems through improvements in practice, equipment, and talent to prevent future disruptions and ensure compliance.
Capital Allocation Strategy and Liquidity
The company maintains a healthy net cash position of ₹8,947 crores as of December 31, 2024, against a debt of ₹466 crores. Cipla aims to address portfolio gaps through acquisitions, product licensing, and in-licensing in India, and by acquiring differentiated assets in the US and other attractive markets. The R&D investment for the quarter was ₹360 crores, approximately 5% of revenue, with a guidance of 5-6% for the future to support pipeline development. The company also reiterated its commitment to a dividend payout ratio of about 30%.